Pharmaceutical

OTCQX:DMPI

On February 17, 2016 DelMar Pharmaceuticals (OTCQX:DMPI) hosted a business update Conference Call and Webcast, to discuss the Company’s finance results for the Second Quarter of the 2016 Fiscal Year Ending December 31, 2015 and business outlook for 2016.

On February 17, 2016 DelMar Pharmaceuticals (OTCQX:DMPI) hosted a business update Conference Call and Webcast, to discuss the Company’s finance results for the Second Quarter of the 2016 Fiscal Year Ending December 31, 2015 and business outlook for 2016.
Listen to the Full Conference Call
DelMar Pharmaceuticals CEO, Jeffrey Bacha, stated:

To date, we’re very pleased that we have five U.S. patents and four international patents that have issued so far, which gives pattern protection in United States into 2033. The benefit there of certainly trumping the seven-year to 10-year market exclusivity available to us from orphan drug protection, as well. But the value of the portfolio and the size of it has grown underneath those eight separate patents families.
So we now have 90 patents moving through the system internationally and four provisional patents pending that were filed in the last 12 months. So you can see that this pattern portfolio is becoming very robust and we expect to bear some very solid fruit that goes along side of the orphan drug protection that we have been granted from the FDA.
So VAL-083 and GBM, yes there’s historical clinical activity in the indication, but the real driver of our excitement here is the fact that the mechanism is different and distinct from those other chemotherapy agents that have shown promise and have been approved in the treatment of the disease. And specifically VAL-083 gets around the activity of a repair enzyme called MGMT, which is correlated with poor patient outcomes in the disease.
The goal here is of course on one hand to get this drug VAL-083 into the hands of clinicians as an approved product for the refractory GBM patients as quickly as possible. There is nothing available for these patients. But the real story and the real goal for the company is not to treat patients that are – has failed Avastin, but it’s really to provide an alternative to temozolomide in the newly diagnosed glioblastoma population in the high expressing MGMT population.

Listen to the Full Conference Call

Featured

MARKETS

Markets
TSX20321.54+35.34
TSXV698.01-2.65
DOW31862.15-66.47
S&P 5003944.45+2.97
NASD11319.34+54.89
ASX7128.80-20.10

COMMODITIES

Commodities
Gold1844.92-22.36
Silver21.85-0.27
Copper4.26-0.05
Palladium1999.00+2.00
Platinum942.00-14.00
Oil110.00+0.23
Heating Oil3.70+0.05
Natural Gas9.12+0.33

DOWNLOAD FREE REPORTS

×